According to the WHO warning, the possibility of new and more dangerous strains of Covid-19 spreading around the world makes it even more difficult to contain the pandemic.
Committee Chairman Didier Houssin acknowledged “disturbing recent trends”. According to him, a year and a half after the WHO first declared a public health emergency, the highest alert level, “we are still chasing this virus and the virus is also chasing us”.
The rapidly spreading variant of Covid-19 threatens efforts to contain the global epidemic. Illustration
Currently, 4 strains of Covid-19 are dominating the global pandemic picture: Alpha, Beta, Gamma, especially the Delta variant that is spreading rapidly. But the committee warned that worse could lie ahead, pointing to the “high probability of new strains emerging and spreading globally”, posing more challenges in terms of pandemic control.
WHO declares strains “concerning” when they are considered more transmissible, more lethal or resistant to vaccines.
“Pandemics remain a global challenge. Countries with access to advanced vaccines and well-resourced health systems are under pressure to fully reopen,” the commission said. On the other hand, “countries with limited access to vaccines are experiencing new waves of infections, seeing eroded public confidence as well as growing economic hardship, and in some cases, instability. society is also growing.
The WHO says that “wearing a mask, keeping distance, hand hygiene and improving ventilation of indoor spaces remain key to reducing transmission”. They also emphasized the need to vaccinate at least 10% of each country’s population by September, as well as increase vaccine sharing between rich and poor countries.
In the face of the rapidly spreading Covid-19 epidemic, the research on drugs to treat Covid-19 has also become more urgent. Recently, the US is testing phase 3 drugs to treat Covid-19 orally and may be on the market by the end of this year. This is good news for all people around the world in the context of the complicated development of the Covid-19 epidemic.
An antiviral drug called Molnupiravir from the US is the most potential candidate for the hope of ending the Covid-19 pandemic in the near future. Molnupiravir drug was developed by the cooperation between two companies Rigibel (Germany) and Merk (USA). Phase 1 and phase 2 clinical trials have been completed with 100% efficacy in Covid-19 patients. After 5 days, the patient’s viral load dropped to a non-contagious threshold.
The phase 3 clinical trial study is also nearing the end with very good results, and the results are expected to be available in the fall of this year. If the research goes well, the drug Molnupiravir will be on the market in the next 4-5 months.
This drug is researched based on the original drug against influenza virus, which inhibits the replication of RNA viruses including SARS-CoV-2, causing the virus to not multiply and be eliminated very quickly, helping patients cured. In particular, the drug has very few side effects, commonly headaches, insomnia.
Molnupiravir is easy to use orally to treat patients with early stage SARS-CoV-2 infection. Accordingly, each patient will take 2 doses per day and maintain for 5 days at home. If the phase 3 study is successful, in the future the treatment of SARS-CoV-2 will be similar to the treatment of other types of flu.
Currently, the US Government has spent about $ 1.2 billion to buy 1.7 million courses of Molnupiravir for Covid-19 patients. If the results are successful, the US FDA will authorize the drug. Since March last year, after detecting millions of mink deaths on farms in the Netherlands and Norway due to a strain of coronavirus, the research team has given the mink drug Molnupiravir. No virus was detected in the sick ferrets after 24 hours. From that result, the research team continues to develop and upgrade the drug Molnupiravir for testing on humans.
On July 9, India’s Hetero Laboratories also asked the regulator to license Molnupiravir for use in emergency programs after initial trial studies showed the drug to be effective in reducing the incidence of cancer. hospitalization and speed up the recovery of mild Covid-19 patients.
The world has recorded 189,624,540 nCoV infections and 4,081,030 deaths, an increase of 484,354 and 6,911, respectively, while 171,289,269 people have recovered, according to real-time statistics site Worldometers.
The US, the world’s largest epidemic area, reported 34.875,458 infections and 624,109 deaths from nCoV, an increase of 27,390 infections and 255 deaths compared to the previous day.
Most US states have recorded an increase in infections due to the Delta mutation. In 47 states, the rate of new cases in the past week was at least 10% higher than the previous week, according to data from Johns Hopkins University. 35 states saw an increase of more than 50%. In Arkansas, hospitals “are now full, and cases are doubling every 10 days.”
According to the Centers for Disease Control and Prevention, a vaccine supply has been available to most Americans for months, but still only 48.3% of the population is fully immunized and rates of new vaccinations are falling. Vaccination rates are down 11% from a week ago and have only reached a quarter of vaccination rates two months ago.
According to WHO statistics, infections skyrocketed in Europe with a daily average of 115,390 cases, an increase of 36% compared to the previous week. The Netherlands increased by 512%, Belgium by 103%, Greece by 97%, France by 81% and Italy by 75%.
Asia alone accounted for nearly a third of new infections in the past week, recording a daily average of 145,840, up 28%, mainly in India with about 44,630 daily cases, up 15%.
Brazil is second only to India with 42,960 daily average cases over the past 7 days, but down 15% from last week. Latin America and the Caribbean recorded an average of 109,096 new cases, down 11%.
An Duong (Th)